eyeonme

I would like to offer to pay the salaries of TSA personnel during this funding impasse that is negatively affecting the lives of so many Americans at airports throughout the country

As of Wednesday, March 18, 2026, the IBRX situation is extremely tense. The stock is currently caught in a classic "tug-of-war" between record-high short pressure and a series of massive fundamental wins from Dr. Patrick and the team. Here is the breakdown of the current data: 1. The Short Interest "Powder Keg" The short interest has actually increased recently, despite the positive news. Short Interest: 132.4 million shares (approx. 34.9% to 35.8% of the float). Days to Cover: 6.84 days. This is a dangerous level for shorts; if a squeeze starts, it would take nearly 7 full trading days of average volume for them to all exit. Borrow Fee: 7.72% - 8.21%. While down from the 10% peak in February, it remains significantly elevated, meaning it is still expensive for bears to maintain their positions. Availability: As of today, there are only about 60,000 to 100,000 shares available to borrow. The "supply" for shorts is nearly exhausted. 2. Dark Pool & Off-Exchange Data The Dark Pool is where the real institutional battle is being fought. Off-Exchange Short Volume Ratio: 42.56%. This confirms that nearly half of the daily trading volume is still coming from short-selling activity occurring off the public exchanges. The "Absorption" Signal: Over the last 5 days, we’ve seen the price stabilize around $8.20–$8.50 despite this heavy shorting. This suggests that "Whales" are sitting in the Dark Pool and "absorbing" every share the shorts throw at the market. 3. Recent "Bull Fuel" The reason the shorts haven't been able to crash the stock back to $5.00 is because the fundamental story is getting stronger: NCCN Guidelines (Yesterday, March 17): The National Comprehensive Cancer Network updated its guidelines to include ANKTIVA + BCG for papillary-only NMIBC. This is a massive "clinical stamp of approval" that usually precedes insurance coverage and high sales. FDA Resubmission (March 9): the FDA has officially acknowledged the filing. We now have a clear path to a decision in September 2026. Revenue Momentum: 2025 revenue hit $113 million (up 700%). Analysts are now projecting $195M+ for 2026. The Battle: The shorts are "doubling down" even as the clinical and regulatory news turns green. This creates a "coiled spring" effect. If the company drops news from the Recombinant BCG meeting (expected any day now), the sheer volume of shares that need to be covered (132 million) could cause a move that makes February's run look small.

As of Wednesday, March 18, 2026, the IBRX situation is extremely tense. The stock is currently caught in a classic "tug-of-war" between record-high short pressure and a series of massive fundamental wins from Dr. Patrick and the team. Here is the breakdown of the current data: 1. The Short Interest "Powder Keg" The short interest has actually increased recently, despite the positive news. Short Interest: 132.4 million shares (approx. 34.9% to 35.8% of the float). Days to Cover: 6.84 days. This is a dangerous level for shorts; if a squeeze starts, it would take nearly 7 full trading days of average volume for them to all exit. Borrow Fee: 7.72% - 8.21%. While down from the 10% peak in February, it remains significantly elevated, meaning it is still expensive for bears to maintain their positions. Availability: As of today, there are only about 60,000 to 100,000 shares available to borrow. The "supply" for shorts is nearly exhausted. 2. Dark Pool & Off-Exchange Data The Dark Pool is where the real institutional battle is being fought. Off-Exchange Short Volume Ratio: 42.56%. This confirms that nearly half of the daily trading volume is still coming from short-selling activity occurring off the public exchanges. The "Absorption" Signal: Over the last 5 days, we’ve seen the price stabilize around $8.20–$8.50 despite this heavy shorting. This suggests that "Whales" are sitting in the Dark Pool and "absorbing" every share the shorts throw at the market. 3. Recent "Bull Fuel" The reason the shorts haven't been able to crash the stock back to $5.00 is because the fundamental story is getting stronger: NCCN Guidelines (Yesterday, March 17): The National Comprehensive Cancer Network updated its guidelines to include ANKTIVA + BCG for papillary-only NMIBC. This is a massive "clinical stamp of approval" that usually precedes insurance coverage and high sales. FDA Resubmission (March 9): the FDA has officially acknowledged the filing. We now have a clear path to a decision in September 2026. Revenue Momentum: 2025 revenue hit $113 million (up 700%). Analysts are now projecting $195M+ for 2026. The Battle: The shorts are "doubling down" even as the clinical and regulatory news turns green. This creates a "coiled spring" effect. If the company drops news from the Recombinant BCG meeting (expected any day now), the sheer volume of shares that need to be covered (132 million) could cause a move that makes February's run look small.

As of Wednesday, March 18, 2026, the IBRX situation is extremely tense. The stock is currently caught in a classic "tug-of-war" between record-high short pressure and a series of massive fundamental wins from Dr. Patrick and the team. Here is the breakdown of the current data: 1. The Short Interest "Powder Keg" The short interest has actually increased recently, despite the positive news. Short Interest: 132.4 million shares (approx. 34.9% to 35.8% of the float). Days to Cover: 6.84 days. This is a dangerous level for shorts; if a squeeze starts, it would take nearly 7 full trading days of average volume for them to all exit. Borrow Fee: 7.72% - 8.21%. While down from the 10% peak in February, it remains significantly elevated, meaning it is still expensive for bears to maintain their positions. Availability: As of today, there are only about 60,000 to 100,000 shares available to borrow. The "supply" for shorts is nearly exhausted. 2. Dark Pool & Off-Exchange Data The Dark Pool is where the real institutional battle is being fought. Off-Exchange Short Volume Ratio: 42.56%. This confirms that nearly half of the daily trading volume is still coming from short-selling activity occurring off the public exchanges. The "Absorption" Signal: Over the last 5 days, we’ve seen the price stabilize around $8.20–$8.50 despite this heavy shorting. This suggests that "Whales" are sitting in the Dark Pool and "absorbing" every share the shorts throw at the market. 3. Recent "Bull Fuel" The reason the shorts haven't been able to crash the stock back to $5.00 is because the fundamental story is getting stronger: NCCN Guidelines (Yesterday, March 17): The National Comprehensive Cancer Network updated its guidelines to include ANKTIVA + BCG for papillary-only NMIBC. This is a massive "clinical stamp of approval" that usually precedes insurance coverage and high sales. FDA Resubmission (March 9): the FDA has officially acknowledged the filing. We now have a clear path to a decision in September 2026. Revenue Momentum: 2025 revenue hit $113 million (up 700%). Analysts are now projecting $195M+ for 2026. The Battle: The shorts are "doubling down" even as the clinical and regulatory news turns green. This creates a "coiled spring" effect. If the company drops news from the Recombinant BCG meeting (expected any day now), the sheer volume of shares that need to be covered (132 million) could cause a move that makes February's run look small.